On the morning of the 4th, Alteogen's stock price is strong. This is because the U.S. Patent and Trademark Office has officially initiated a patent invalidation trial (PGR) that Alteogen filed against its competitor Halozyme. Industry experts are evaluating that the uncertainty surrounding the launch of Keytruda SC, in which Alteogen's technology is utilized, has been removed.
As of 9:21 a.m. on the 4th, Alteogen's stock is trading at 384,000 won, up 34,000 won (9.71%) from the previous trading day in the KOSDAQ market.
Earlier, on the 3rd, Alteogen announced that formal trial proceedings have been initiated regarding the patent invalidation trial filed by its partner MSD against the competitor Halozyme's patent.
Eom Min-yong, a researcher at Shinhan Investment Corp., noted, "As the U.S. Patent and Trademark Office has initiated formal procedures for the patent PGR of Halozyme's MDASE, most of Halozyme's claims have been neutralized," adding that "the uncertainty regarding the launch of Keytruda SC in October has been removed."
Kim Sun-a, a researcher at Hana Securities, also projected, "This decision to initiate proceedings can serve as a positive factor in alleviating the uncertainty from external partners regarding Alteogen's technology."